Endocyte, Inc. Common Stock
ECYT
ECYT was delisted on the 20th of December, 2018.
101 hedge funds and large institutions have $228M invested in Endocyte, Inc. Common Stock in 2013 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 40 increasing their positions, 33 reducing their positions, and 25 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 33
5% more capital invested
Capital invested by funds: $216M → $228M (+$11.7M)
9% less funds holding
Funds holding: 111 → 101 (-10)
40% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 25
80% less call options, than puts
Call options by funds: $935K | Put options by funds: $4.79M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$20.1M |
| 2 |
PA
Pinnacle Associates
New York
|
+$9.83M |
| 3 |
RIM
RS Investment Management
San Francisco,
California
|
+$7.59M |
| 4 |
PA
Perceptive Advisors
New York
|
+$5.53M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$8.69M |
| 2 |
MG
Meditor Group
Hamilton,
Bermuda
|
-$4.4M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$2.38M |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$2.04M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$2.04M |
ECYT Hedge Fund Activity: Q3 2013 in Review
101 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q3 2013, worth a combined $228M — up 5.4% from $216M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ECYT and 15 opened new positions — a net loss of 10 holders — while 33 trimmed existing stakes and 40 added.
The largest buyer was Fidelity Investments, adding an estimated $20.1M. The largest seller was OrbiMed, exiting entirely with an estimated $8.69M sold.
- 101 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q3 2013, down from 111 in Q2 2013.
- Funds reported $228M of Endocyte, Inc. Common Stock stock for Q3 2013, up 5.4% quarter-over-quarter.
- 15 funds opened new Endocyte, Inc. Common Stock positions in Q3 2013 and 25 closed out, a net change of -10 holders.
- The largest Endocyte, Inc. Common Stock buyer in Q3 2013 was Fidelity Investments, an estimated $20.1M added.
- The largest Endocyte, Inc. Common Stock seller in Q3 2013 was OrbiMed, an estimated $8.69M sold.
Based on aggregated 13F filings for Q3 2013.